Myotubularins (MTM) are a large family of evolutionarily conserved lipid phosphatases (PT) that specifically dephosphorylate the 3Ј position of phosphatidylinositol 3-phosphate [PI(3)P] and PI(3,5)P 2 (28, 39) . Fourteen MTMs in mammalian cells have been identified, and they can be divided into six subgroups based on sequence alignment and phylogenetic comparison. Members of one of these subgroups lack phosphatase activity due to a mutation in a critical residue within the phosphatase domain. MTM1, the founding member of this gene family, is mutated in X-linked myotubular myopathy, and MTMR2 and MTMR13 are mutated in Charcot-Marie-Tooth (CMT) syndrome type 4B (3, 30, 37) . In addition to containing a phosphatase domain, most MTMs are composed of a GRAM domain which may mediate association of MTMs with membranes, a Rac-induced localization domain which mediates the association with Rac-induced membrane ruffles, and a C-terminal coiled coil (CC) domain (10, 28, 29, 39) . Recent data have indicated that the MTM CC domains mediate specific heterodimerization between a MTM (PT active) and a MTM mutant for PT activity (PT inactive) and that this interaction is critical for MTM regulation, at least in part, by up-regulating PT activity (24, 33, 34) .
The genetic finding that loss of MTM function leads to specific phenotypes in mammals and Caenorhabditis elegans indicates that different MTM members, even within the same subgroup, are not functionally redundant with one another. This has led to the suggestion that different MTMs regulate specific subcellular pools of PI(3)P and PI(3,5)P 2 whose function is to couple to specific downstream signaling pathways. However, as of yet, the specific downstream events regulated by different MTMs are not known. To gain insight into the specific functions and targets of MTMs, we screened a C. elegans yeast two-hybrid cDNA library for proteins that interacted with the C. elegans MTMR6 (ceMTMR6) CC domain.
MATERIALS AND METHODS
Yeast two-hybrid system. The ProQuest two-hybrid system (Invitrogen) was used according to the manufacturer's protocol to screen a C. elegans cDNA library (Invitrogen) for proteins that bound the CC domain (amino acids [AA] 508 to 570) of CeMTMR6 (F53A2.8). The CC domains of CeMTMR6, CeMTMR1 (CeY110ATA.5, amino acids 580 to 613), and CeMTMR3 (CeT24A11.1, amino acids 700 to 750) were amplified by PCR and cloned into the vector pDBLeu (Invitrogen). These constructs were then cotransfected with the original MTMR6 CC domain-interacting clone (the C-terminal 126 amino acids of F08A10.1 [AA 781 to 907]), and interaction was tested according to the manufacturer's protocol. The CC domains were determined using a program developed by Lupas et al. (31) .
Constructs, cell lines, and cell culture. Flg-tagged Human K Ca 3.1 (SK4) and Rat K Ca 2.2 (SK2) were cloned into pcDNA3 and transfected into CHO cells using Lipofectamine (Clontech). Geneticin-resistant colonies were isolated, and homogeneous expression of K Ca 3.1 (CHO-K Ca 3.1) and K Ca 2.2 (CHO-K Ca 2.2) was confirmed by immunofluorescence using anti-Flg antibodies. Green fluorescent protein (GFP)-tagged human MTMR6, MTMR8, and MTMR1 were generated by amplifying the various cDNAs by PCR and then cloning in frame into the vector pEGFP-C1 to generate an amino-terminal tagged GFP fusion protein.
MTMR6 mutant for PT activity [MTMR6-PT(dead)] in which the catalytic cysteine at position 336 was mutated to serine was generated using a Transformer mutagenesis kit (Clontech) and MTMR6 deleted of its CC domain was generated by PCR using a 5Ј sense primer containing the amino-terminal ATG and a 3Ј antisense primer 5Ј to amino acid 514. MTM1/6CC was generated by overlapping PCR to generate a chimeric molecule that consisted of AA 1 to 546 of MTM1 and AA 512 to 560 of MTMR6. Accession numbers for the various constructs are as follows: AAP3609 for human SK4, NP_062187 for rat SK2, CAI39897 for human MTMR6, NP_000243 for human MTM1, and CAI43025 for human MTMR8.
Immunoprecipitation, Western blotting, and immunofluorescence. HEK293 cells were transfected with GFP-tagged MTMR6, MTMR8, or MTMR6 mutants as described above together with Flg-tagged K Ca 3.1 or Flg-tagged K Ca 2.2. Cell lysis, immunoprecipitation, and Western blotting were performed as previously described (1) .
To determine whether overexpression of MTMR6 affects the amount of K Ca 3.1 at the plasma membrane (PM), MTMR6 was transfected with K Ca 3.1 containing an hemagglutinin (HA) epitope tag inserted into the extracellular loops between S3 and S4. Previous studies have demonstrated that K Ca 3.1 with this extracellular tag functions normally and can be specifically detected at the PM by immunofluorescence on nonpermeabilized cells (38) . CHO cells were transfected with HA-K Ca 3.1 together with the GFP control or the GFP-tagged MTMR6 wild type (GFP-MTMR6-WT), and cell surface expression was performed on nonpermeabilized cells using antibodies to HA as described previously (38) . Patch clamping. For electrophysiological studies, CHO-K Ca 3.1 cells were transfected with GFP-tagged constructs as indicated above and plated on 12-mm-diameter coverslips. After 24 to 48 h, a coverslip was positioned in a recording chamber, and patch clamping was performed under one of two experimental conditions that yielded similar results. , and a bath solution containing NaCl (140 mM), KCl (5 mM), CaCl 2 (1 mM), MgCl 2 (1 mM), HEPES (10 mM), and glucose (10 mM). Patch clamp pipettes had resistances ranging between 2 and 4 M⍀. We performed whole-cell patch clamp recordings at room temperature. Current-voltage (IV) relationships were measured using ramp voltage clamp protocols (at 15-s intervals) from a holding potential of Ϫ70 mV to Ϫ120 mV, followed by ramp depolarization to ϩ60mV (symmetrical ramp rate of 0.18 mV · ms Ϫ1 ). The current-voltage relationship was obtained by plotting the current during the depolarizing ramp phase as a function of the corresponding voltage. In some experiments, a square step voltage clamp protocol was used (200-ms duration) to assess alterations in kinetics. Membrane currents filtered (Ϫ3 dB at 1 kHz) and digitized at 10 kHz (pClamp 9.2 with Digidata 1200 ADC interface; Axon Instruments). Cell capacitance and pipette series resistances were compensated (usually Ͼ80%) and were obtained using the "membrane test" function of Clampex. Whole-cell current density was expressed as pA/pF.
Currents recorded from stably transfected cells were verified to be Ca 2ϩ -activated K ϩ currents by (i) their sensitivity to cytosolic Ca 2ϩ , (ii) the dependence of the reversal potential on the extracellular K ϩ concentration, (iii) their absence in parental CHO cells, (iv) voltage-independent gating, and (v) pharmacological sensitivities (K Ca 3.1 was inhibited by Tram 34, but not apamin, whereas K Ca 2.2 was inhibited by apamin but not by Tram 34) .
To determine whether PI(3)-kinase inhibition affects channel activity, stably transfected cells were treated with the PI(3) kinase [PI(3)K] inhibitor LY294002 (10 M) or wortmannin (100 nM) 15 min prior to patch clamping, and the IV relationship was performed as described above. Phosphatidylinositols (C 8 ) were purchased from Echelon Biosciences and used according to the manufacturer's specifications. Briefly, lipids were resuspended in water and sonicated for 20 min and used at concentrations of 100 nM in the pipette solution.
RESULTS

Identification of a calcium-activated K
؉ channel (F08A10.1) that specifically binds the CC domain of ceMTMR6. One of the C. elegans ceMTMR6 CC domain-interacting proteins we identified in the yeast two-hybrid assay was a calcium-activated K ϩ channel (F08A10.1) that is most similar to the mammalian intermediate K ϩ channel, K Ca 3.1 (also known as KCa4, IKCa1, hIK1, or SK4), but also has significant similarity to other small-conductance (SK) channels (4, 6, 7). The original interacting clone was only a partial cDNA of F08A10.1 and encoded only the C-terminal 126 amino acids of F08A10.1 (AA 781 to 907), of which AA 811 to 895 is strongly predicted to be a CC domain. Thus, the interaction between CeMTMR6 and F08A10.1 is mediated by CC domains on both proteins. In addition, the interaction was specific; the same clone failed to bind the CC domain of both CeMTMR3 and CeMTMR1 (Fig.  1A) .
Mammalian MTMR6 family members interact with K Ca 3.1 in cells. Mammalian cells contain four genes encoding small or intermediate K ϩ channels. Three of these belong to the same subfamily (K Ca 2.1, K Ca 2.2, and K Ca 2.3, also named SK1-3) (4, 6, 7). Within the SK gene family, K Ca 3.1 (also named SK4) diverges from other SK family members, suggesting that SK4 represent a member of a new emerging subfamily of SK genes. Both the small conductance and intermediate conductance K (Fig. 1B) and has the highest homology to K Ca 3.1. While C. elegans has only one MTMR6 subgroup member, mammals have three, MTMR6, 7, and 8 (28, 39, 42) .
To determine whether mammalian MTMR6 family members interact with K Ca 3.1 in cells, we tested whether human MTMR6 (hMTMR6) or a related subfamily member, hMTMR8, coimmunoprecipitate with K Ca 3.1. HEK-293 cells were transfected with GFP-tagged MTMR6 or GFP-tagged MTMR8 together with Flg-K Ca 3.1. We found that both GFPtagged MTMTR6 and GFP-tagged MTMR8 coimmunoprecipitate with Flg antibodies (Fig. 1C, lanes 6 and 9) . The interaction between MTMR6 and K Ca 3.1 did not require phosphatase activity since MTMR6-PT(dead), in which the catalytic cysteine at position 336 was changed to serine, also coimmunoprecipitated to a similar degree as the MTMR6-WT (Fig.  1C, compare lanes 7 and 9) . In contrast, mutation of the MTMR6 CC domain by truncating MTMR6 at amino acid 514, which is predicted to delete the CC domain (AA 514 to 546), plus the C-terminal AA 547 to 621, markedly diminished binding (lane 8) despite similar levels of expression (Fig. 1C , compare lanes 3, 4, and 5) and similar amounts of immunoprecipitated K Ca 3.1 (lower part of lanes 6 to 10). In similar experiments, we found that K Ca 2.2 (SK2) also coimmunoprecipitated with MTMR6, although to a lesser extent than K Ca 3.1 (Fig. 1C, lanes 11 and 12) .
MTMR6 inhibits K Ca 3.1 channel activity. To determine whether MTMs regulate K Ca 3.1 function, a CHO cell line stably expressing Flg-tagged K Ca 3.1 (CHO-K Ca 3.1) was generated and the effect of overexpressed GFP-tagged MTMR6 on channel activity was determined. The IV relationships from Fig. 2A . Also shown is the IV curve following application of Tram 34. In contrast to these control cells, K Ca 3.1 currents were markedly reduced when CHO-K Ca 3.1 cells were cotransfected with GFP-MTMR6 (Fig. 2B) , without affecting the reversal potential (Fig. 2B ) or time dependence of the currents (not shown). The inhibition of K Ca 3.1 by MTMR6 required both MTMR6 CC and PT domains, because mutation of either domain abrogated the inhibitory effects of MTMR6 (Fig. 3) . In fact, current activity was reproducibly greater in CHO-K Ca 3.1 cells transfected with MTMR6-PT(dead) than in GFP-transfected cells, suggesting that this mutant may function as dominant negatives to inhibit MTMR6 family members endogenously expressed in these cells. Immunofluorescence studies demonstrated that expression of GFP-MTMR6 or treatment of cells with the PI(3) kinase inhibitor wortmannin (which also inhibits K Ca 3.1; see Fig. 6 ) did not affect cell surface expression of K Ca 3.1, indicating that altered trafficking of K Ca 3.1 to the plasma membrane does not account for the decrease in current in GFP-MTMR6-transfected cells (Fig. 4) . We next assessed whether the overexpression of GFP-MTM6 inhibits K Ca 2.2 channel activity ( Fig. 2C and D) . Using a similar approach to that described for K Ca 3.1, stable CHO-K Ca 2.2 cell lines were generated and the effect of GFP-MTM6 overexpression on K Ca 2.2 channel activity was assessed. A typical K Ca 2.2 current in the GFP control-transfected CHO- Fig. 2C . The specificity of the current was documented using criteria similar to those described above for K Ca 3.1, with the exception that K Ca 2.2 current was inhibited by apamine (Fig. 2C) and not by Tram 34 (data not shown). In contrast to K Ca 3.1, overexpression of GFP-MTMR6 did not inhibit K Ca 2.2 channel activity (Fig. 2D) . Thus, MTMR6 does not inhibit all SK channels. Future studies will address whether MTMR6 inhibits the K Ca 2.1 or K Ca 2.3 channel. The CC domain of MTMR6 is sufficient to enable other MTMs to inhibit K Ca 3.1 channel activity. In contrast to MTMR6, GFP-MTM1 did not inhibit K Ca 3.1 (Fig. 3) . However, a chimeric MTM1 in which the MTM1 CC domain was swapped for the MTMR6 CC (MTM1/6CC)-inhibited K Ca 3.1 to a similar degree as MTMR6, indicating that the CC domain is sufficient to confer target specificity (Fig. 3) .
K Ca 2.2 cells is shown in
MTMR6 inhibits K Ca 3.1 by decreasing intracellular levels of PI(3)P. One function of MTMR6 binding to K Ca 3.1 may be to localize MTMR6 activity to the plasma membrane adjacent to K Ca 3.1, thereby enabling MTMR6 to selectively dephosphorylate a local PI(3)P pool in a lipid microdomain adjacent to K Ca 3.1. The finding that overexpression of MTMR6 turns off channel activity predicts that for this model to be correct, intracellular application of PI(3)P or PI(3,5)P 2 should reacti- (Fig. 5A to C). Phosphoinositide PI(3)P is required for K Ca 3.1 activity. Our data so far demonstrate a key role for PI(3)P in regulating K Ca 3.1 channel activity. We performed additional experiments with PI(3)K inhibitors, which are predicted to decrease PI(3)P levels and hence, according to our model, inhibit K Ca 3.1 channel activity. Treatment of CHO-K Ca 3.1 cells with the specific PI(3) kinase inhibitors LY294002 or wortmannin for 15 min prior to patch clamping completely abrogated channel activity (Fig. 6A to C) . The inhibition of K Ca 3.1 by LY294002 or wortmannin was due to decreased levels of PI(3)P, because channel inhibition by LY294002 or wortmannin could be completely restored by dialysis of 100 nM PI(3)P into the cell through the patch pipette (Fig. 7A to C) . The rescue of current activity was specific to PI(3)P, since similar experiments using PI(4)P, PI(5)P, PI(3,5)P 2 , PI(3,4)P 2 , or PI(3,4,5)P 3 in the pipette did not restore current activity over a time course of 5 min in cells treated with LY294002 or with wortmannin ( Fig.  7C and data not shown) . Neither wortmannin nor LY294002 inhibited K Ca 2.2 ( Fig. 6D to F) . These data, together with the finding that the overexpression of MTMR6 did not inhibit K Ca 2.2, indicates that, unlike K Ca 3.1 channels, K Ca 2.2 is not regulated by PI(3)P.
DISCUSSION
Our finding that MTMR6 inhibits K Ca 3.1 channel activity provides the first identification of a downstream target that is specifically regulated by an MTM family member. Moreover, this is the first demonstration that K Ca 3.1 is specifically regulated by PI(3)P and that K Ca 3.1 requires PI(3)P for channel activity. Our data, when taken together, support a model whereby binding of the CC domain of MTMR6 to the CC domain on K Ca 3.1 leads to selective dephosphorylation of PI(3)P in a lipid microdomain adjacent to K Ca 3.1, resulting in a decrease in K Ca 3.1 channel activity.
An important role for CC domains in regulating specific functions of MTMs has been established. However, unlike the findings reported here, previous studies have focused on the importance of CC domains in mediating specific heterodimerization between a PT-active and PT-inactive MTM family member (24, 33, 34) . The importance of this interaction is supported by both biochemical and genetic data. Genetic evidence with humans and C. elegans has shown that mutations in a PT-active and a PT-inactive MTM that heterodimerize give rise to similar phenotypes; mutations in a PT-active (MTMR2) and PT-inactive (MTMR13) MTM give rise to CMT type 4B in humans and mutations in a C. elegans PT-active (CeMTM6), and PT-inactive (CeMTM9) MTM lead to defective fluid phase endocytosis in coelomocytes in C. elegans (3, 8, 37) . The finding that heterodimerization increases PT activity has led to the idea that this interaction is critical, at least in part, for optimal PT activity. We now show that MTM CC domains have an additional function, to direct MTMs to specific targets which are regulated by PI(3)P. We propose that at least part of the specificity in MTM function is mediated by the recruitment of different MTM CC domains to specific targets. This model is supported by our finding that while MTM1 does not inhibit K Ca 3.1, a chimeric MTM1 containing the MTMR6 CC domain inhibits K Ca 3.1 channel activities. Thus, once MTM1 is targeted to the channel, other domains on MTM1 that are required to inhibit K Ca 3.1, such as the PT domain, function similarly in MTMR6 and MTM1. The idea that CC domains specifically target MTMs may also have important implications for understanding the mechanisms whereby loss of MTMs leads to disease. Although altered levels of PI(3)P or PI(3,5)P 2 likely account for clinical disease in X-linked myotubular myopathy and CMT, downstream targets or signaling pathways that are altered due to loss of MTM function are not yet known. The identification of binding partners for the CC domains on these MTMs (MTM1, MTMR2, and MTMR13) may thus provide important insights into the mechanisms whereby loss of MTMs leads to disease.
One important question that needs to be addressed is whether a CC domain-interacting protein forms a trimolecular complex with a PT-live and a PT-inactive MTM. With regard to MTMR6, genetic and biochemical studies have indicated that MTMR6 family members heterodimerize specifically with MTMR9 (PT inactive) (33, 42) . We have found that while C. elegans that has mutations in either MTMR6 and MTMR9 is defective in fluid phase endocytosis, RNA interference that target MTMR6, but not MTMR9, rescues lethality for vps34 in the C. elegans mutant. These data indicate that MTMR6, under some circumstances, can act independently of MTMR9. We have thus far been unable to identify a function of F53A2.8 for C. elegans or whether F53A2.8 functions in a pathway similar to CeMTMR6; C. elegans fed or injected with RNA interference to F53A2.8 to exhibit any obvious phenotype. Future studies will address whether inhibition of a specific target (K Ca 3.1) by MTMR6 in mammalian cells requires MTMR9.
An important physiological role for K Ca 3.1 channels is to regulate membrane potential and calcium signaling in a variety of cell types. In response to a rise in cytosolic calcium, K Ca 3.1 channels are activated via calmodulin bound to the C terminus of K Ca 3.1, leading to cross-linking of the channel, pore open- (13, 14) , although direct phosphorylation of K Ca 3.1 has not been shown. In addition, arachidonic acid has been shown to inhibit K Ca 3.1 by binding the S5-pore-S6 region (16) . We now provide evidence that K Ca 3.1 is activated by PI(3)P and that MTMs negatively regulate K Ca 3.1, possibly by decreasing the concentration of PI(3)P in the plasma membrane. The finding that K Ca 2.2 is not regulated by PI(3)P provides further evidence that while K Ca 2.2 and K Ca 3.1 share conserved amino acid sequences and structure and both require Ca 2ϩ for activation, they also have distinct mechanisms for regulation. This is consistent with previous studies that demonstrated that K Ca 3.1, but not K Ca 2.2, is regulated by kinases and arachidonic acid (14, 16) .
While a number of channels have been shown to be regulated by phosphoinositides, we believe that this is the first demonstration of specific regulation of a channel by PI(3)P. It is not clear whether PI(3)P activates K Ca 3.1 directly or whether PI(3)P activates K Ca 3.1 indirectly by binding and recruiting a different molecule to a membrane (such as the PM), which then activates K Ca 3.1. Direct regulation of channels, such as the Ca 2ϩ transporter NCX1 and voltage-gated K channels, by PIP 2 involves the interaction of PIP 2 with cationically charged inhibitory domains in the cytoplasmic face of the channel, leading to conformational change and channel activation (17, 18) . The ability of PIP 2 to activate channels under these circumstances has been attributed to its high physiologic concentrations (Ͼ1% of anionic phospholipids), which are far in excess of the concentration of PI(3)P in membranes. Thus, it is unlikely that PI(3)P regulates K Ca 3.1 by a similar mechanism. Rather, we favor the hypothesis that PI(3)P regulates K Ca 3.1 by specifically binding an as-yet-unidentified PH or FYVE domain-containing protein, which in turn regulates K Ca 3.1. In support of this model, we have preliminary evidence that PI(3)P does not activate K Ca 3.1 in isolated membrane patches (data not shown).
The finding that MTMR6 family members downregulate K Ca 3.1 suggests that this family of PI(3)P PTs plays unexpected roles in downregulating biological responses that are mediated by K Ca 3.1. K Ca 3.1 is required for optimal Ca 2ϩ influx which, in turn, leads to proliferation by a variety of cells, including T lymphocytes, keratinocytes, vascular smooth muscle cells, and cancer cells (2, 5, 12, 15, 21, 25, 27, 40) . In response to stimulation, K Ca 3.1 is upregulated in naïve and central memory T cells and naïve and memory B cells (12, 15, 23, 40, 41) . Moreover, K Ca 3.1 is required for proliferation of preactivated naïve T cells and naive B cells, as demonstrated by the finding that the specific K Ca 3.1 inhibitor Tram 34 suppresses proliferation of these T and B cell subsets (15, 41) . K Ca 3.1 is also upregulated in proliferative vascular smooth muscle cells, and the inhibition of K Ca 3.1 inhibits angioplasty-induced restenosis in animal models (27) . K Ca 3.1 also contributes to the proliferation of a number of (9, 20, 32) . Agonists of K Ca 3.1 have been proposed as therapy for cystic fibrosis, in which enhanced K ϩ secretion via K Ca 3.1 can be a means to promote Cl Ϫ secretion. However, only poor K Ca 3.1 agonists exist, and they are ineffective because they result in downregulation of K Ca 3.1 (26, 35) . Thus, the inhibition of MTM6 family members may provide a novel target strategy for upregulating K Ca 3.1 activity. 
